ClinicalTrials.gov
ClinicalTrials.gov Menu

The Prolonged Use of Topiramate for Preventing Migraine Headaches (PROMPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00216619
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : July 2, 2014
Sponsor:
Information provided by (Responsible Party):
Janssen Pharmaceutica N.V., Belgium

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness (beyond 6 months) of individualized doses (100 to 200 milligrams) of topiramate for the prevention of migraine headaches over a period of 26 weeks.

Condition or disease Intervention/treatment Phase
Migraine Drug: Topiramate Drug: Topiramate - Placebo Phase 3

Detailed Description:
Previous studies have shown that topiramate is effective in preventing migraine headaches. This study will start with a 4-week baseline period in which no treatment is given, followed by a 26-week period in which each patient's dose is adjusted and then kept stable for 4 weeks. The dose will start at 25 milligrams of topiramate per day and will be increased 25 milligrams per day once weekly and then raised to either the target--100 milligrams per day--or the maximum dose that is well tolerated up to 200 milligrams per day. Patients randomized to receive topiramate will remain on that dose. The comparison phase of the study is a 26-week period in which the change in migraine days of patients on topiramate (taking at least 50 milligrams per day) is compared with the change in migraine days for patients on the placebo. Also studied will be the patients' health-related quality of life as assessed by questionnaires filled out at specific visits as well as the patients' views of the safety and tolerability of topiramate. The study hypothesis is that the number of migraine days, periods, and attacks during the last 4 weeks of the double-blind phase, relative to the last 4 weeks of the open-label phase, is reduced more in the topiramate group than the placebo group. During open-label (26-weeks) and double-blind phase (26-weeks), patients receiving topiramate will take 25 milligrams to 100 milligrams daily by mouth; increased by 25 milligrams per day once weekly; dose cannot exceed 200 milligrams per day and must be stable for the last 4 weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 834 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention
Study Start Date : November 2003
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine
Drug Information available for: Topiramate

Arm Intervention/treatment
Experimental: Open Label Phase
Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
Drug: Topiramate
topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.

Experimental: Double Blind and Roll Out Phase
the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
Drug: Topiramate
topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.

Drug: Topiramate - Placebo
the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)




Primary Outcome Measures :
  1. Change in migraine days compared between the topiramate group and placebo group at the last 4 weeks of the open-label phase and the final 4 weeks of the placebo-controlled phase [ Time Frame: Last 4 weeks of Open Label (OL) Phase and Double Blind (DB) Phase ]

Secondary Outcome Measures :
  1. Patient's Satisfaction [ Time Frame: Visit 6 ]
    at the end of the OL Phase and at the end of the DB Phase

  2. Health related quality of life as recorded in patient questionnaires (MIDAS and SF-12) [ Time Frame: Visit 2, Visit 6, Visit 10 ]
    At the start of the OL Phase; at the end of the of the OL Phase and at the end of the DB Phase

  3. Health related quality of life as recorded in patient questionnaire (HIT-6) [ Time Frame: Visit 2, Visit 4, Visit 6, Visit 8, Visit 10 ]
    HIT-6 extra questioned at Week 8 and Week 34



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Established history of migraine for at least one year;
  • Migraine meets HIS (International Headache Society) criteria
  • An average of at least 4 monthly migraine days during the 3 months preceding trial entry
  • Capable of keeping trial records; Exclusion Criteria:
  • Patient used migraine prophylactic medication in the month prior to trial entry (flunarizine: 3 months prior to entry)
  • Patient had failed (lack of efficacy) more than two adequate previous regimens of migraine prophylactic medications
  • Patient had a history of severe drug allergy or hypersensitivity
  • Patient overused analgesics, opiates, ergots and/or triptans
  • Patient had been using topiramate regularly

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00216619


  Show 70 Study Locations
Sponsors and Collaborators
Janssen Pharmaceutica N.V., Belgium
Investigators
Study Director: Janssen Pharmaceutica N.V. Clinical Trial Janssen Pharmaceutica N.V.

Additional Information:
Publications of Results:
Responsible Party: Janssen Pharmaceutica N.V., Belgium
ClinicalTrials.gov Identifier: NCT00216619     History of Changes
Other Study ID Numbers: CR003931
2005-000321-29 ( EudraCT Number )
TOPMAT-MIG-303 ( Other Identifier: Janssen CTMS ID )
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: July 2, 2014
Last Verified: July 2014

Keywords provided by Janssen Pharmaceutica N.V., Belgium:
chronic migraine
Topiramate
migraine
headache
chronic headache

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Topiramate
Anticonvulsants
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents